HomeClinical TopicsFDA approves treatment for adults with relapsed or refractory acute myeloid leukemia

FDA approves treatment for adults with relapsed or refractory acute myeloid leukemia

Author(s):

On Nov. 28, the FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Read more via U.S. Food & Drug Administration.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...